calendardigital-marketingit-solutionslocation-dotlogo-footertech-journal-logo-footerweb-development

Open filters Close filters

UncategorizedBTLJ Blog
February 8th, 2016
In May 2015, Mylan Pharmaceuticals appealed to the Third Circuit after the lower court dismissed its case against Warner Chilcott, which was predicated on a practice called product-hopping. While we await the ruling which is due to come later this year, here is some background information on the developing area ...
BTLJ Blog
November 10th, 2014
On October 24, 2014, Amgen filed a complaint against Sandoz, the generic arm of Novartis Group, asserting three causes of action: 1) unfair competition under Cal. Bus. & Prof. Code § 17299 et seq.; 2) conversion; and 3) patent infringement. Amgen filed the complaint in response to Sandoz’s July 2014 ...